<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum></forum>
<forum_title></forum_title>
<discussion_title>Rituximab plus Dose-Dense Chemotherapy for Burkitt Lymphoma - NEJM Journal Watch</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.jwatch.org/na41053/2016/05/13/rituximab-plus-dose-dense-chemotherapy-burkitt-lymphoma</topic_url>
<topic_text>
Ribrag V et al. Lancet 2016 Apr 11. Jabbour E and Kantarjian H. Lancet 2016 Apr 11. 
This article requires a subscription for full access. NEJM Journal Watch articles published within the last six months are available to subscribers only. Articles published more than 6 months ago are available to registered users. Access Options 
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.jwatch.org/na41053/2016/05/13/rituximab-plus-dose-dense-chemotherapy-burkitt-lymphoma</post_url>
<post_date>20160513</post_date>
<post_time></post_time>
<username></username>
<post>
Ribrag V et al. Lancet 2016 Apr 11. Jabbour E and Kantarjian H. Lancet 2016 Apr 11. 
This article requires a subscription for full access. NEJM Journal Watch articles published within the last six months are available to subscribers only. Articles published more than 6 months ago are available to registered users. Access Options 
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image></main_image>
</document>
